Last updated: February 9, 2026
Case Overview
Orphalan SA initiated litigation against Novitium Pharma LLC on March 7, 2023, in the U.S. District Court for the District of New Jersey. The suit alleges patent infringement concerning a formulation of a pharmaceutical compound, specifically targeting Novitium’s alleged unauthorized use of a patented drug composition.
Claims and Allegations
- Patent Violations: Orphalan claims that Novitium infringed U.S. Patent No. 10,658,314, issued on May 19, 2020. The patent covers a specific modified-release formulation of a therapeutic agent used for treating neuromuscular disorders.
- Infringing Activities: The complaint states that Novitium has marketed, sold, or distributed generic versions of the patented formulation without authorization, violating rights secured by the patent.
- Damages Sought: Orphalan seeks injunctive relief to prevent further infringement, monetary damages including disgorgement of profits, and attorney’s fees.
Procedural Status
- The complaint was filed on March 7, 2023.
- On March 15, 2023, Novitium filed a motion to dismiss based on alleged non-infringement and invalidity of the patent.
- Discovery proceedings have not yet commenced; the case remains in early stages of litigation.
Legal Context
The case hinges on the interpretation of the patent claims and whether Novitium’s generic formulation infringes those claims. The court will evaluate:
- Claim Construction: How the patent claims are interpreted, drawing on the intrinsic record (patent specification and claims) and relevant patent law principles.
- Infringement Analysis: Whether Novitium’s activities fall within the scope of the patent claims, considering literal infringement and doctrine of equivalents.
- Patent Validity: Whether prior art or obviousness precludes the patent’s enforceability.
Market and Strategic Implications
- Patent Strength: The patent’s broadness and its claims' scope will influence the outcome and potential settlement discussions.
- Industry Trends: The case is part of a broader trend where patent holders aggressively defend rights against generic manufacturers, especially in high-value therapeutics and novel delivery systems.
- Potential Outcomes:
- If Orphalan prevails: Novitium may be required to cease sales, pay damages, and possibly license the patent.
- If Novitium prevails: The patent could be invalidated or interpreted narrowly, allowing generic market entry.
Related Cases and Regulatory Context
- Similar patent litigation has targeted biosimilar and complex drug formulations, emphasizing issues of patent scope and inventive step.
- The case interacts with ongoing debates about patent protections versus generic access, particularly in the pharmaceutical sector regulated by the FDA.
Key Takeaways
- The litigation centers on patent infringement claims pertaining to a specific pharmaceutical formulation.
- The outcome depends heavily on patent claim interpretation and validity defenses.
- Timelines remain uncertain, but early filings indicate readiness for protracted dispute resolution.
- Strategic stakes include market exclusivity and potential revenue losses for Novitium if infringement is proven.
- The case reflects ongoing patent enforcement efforts in the biopharmaceutical sector.
FAQs
1. What is the core patent involved in this litigation?
U.S. Patent No. 10,658,314, covering a modified-release formulation of a neuromuscular disorder drug.
2. What are the primary legal issues?
Whether Novitium’s generic product infringes the patent’s claims and whether the patent is valid in light of prior art.
3. What defenses might Novitium raise?
Invalidity arguments based on novelty, obviousness, or non-infringement due to claim interpretation disputes.
4. How could this case impact the pharmaceutical market?
A ruling in favor of Orphalan could delay generic entry, maintaining market exclusivity; a ruling favoring Novitium would enable market competition.
5. What is the typical timeline for such patent litigation?
Most patent cases resolve within 18 to 36 months, depending on motions, discovery, and settlement negotiations.
Citations
[1] U.S. District Court for the District of New Jersey, Complaint, Orphalan SA v. Novitium Pharma LLC, Case No. 1:23-cv-01079, March 7, 2023.
